Aug 12, 2020
IDEAYA Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update
Mar 16, 2020
2020 PARP Inhibitors Industry & Pipeline Insights
Mar 11, 2020
IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration for PARG, a DDR-Based Synthetic Lethality Target, Evaluating DNA Replication Vulnerabilities
Dec 10, 2019
Small Molecule Oncology Drug Market Forecast to Exceed $66 Billion in 2019
Sep 30, 2019
Synthetic Lethality-based Drugs and Targets Market, 2030
Sep 05, 2019
Theragnostics Signs Agreement with AstraZeneca
Jun 04, 2019
Ovarian Cancer Disease Coverage Forecast and Market Analysis to 2023
Jun 01, 2019
Sierra Announces Promising Preliminary Efficacy in SRA737 Clinical Program & Outlines Potential Path to Registration
May 08, 2019
Sierra Oncology Reports First Quarter 2019 Results
Apr 03, 2019
Epic Sciences Unveils New Liquid Biopsy Test to Predict Sensitivity to PARP Inhibitors in Prostate Cancer Trial
Mar 31, 2019
Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is Active Against Lymphomas and Solid Tumors, Synergistic with PARP Inhibitors
Feb 28, 2019
Theragnostics Ltd Expands Oncology Portfolio With Licensing of radioPARP Inhibitor
Feb 19, 2019
Alkermes and Clovis Oncology Initiate Research Collaboration to Explore Combination Cancer Therapies
Feb 07, 2019
CStone and IMPACT Therapeutics' clinical collaboration progresses to IND filing acceptance for CS1001+IMP4297 combination therapy
Jan 23, 2019
Sierra Oncology to Present at the DNA Damage Response Therapeutics Summit
Nov 29, 2018
Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
Aug 24, 2018
2018 Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report
Aug 03, 2018
IMPACT Therapeutics Raises $30 Million In Series C Financing
Jul 10, 2018
Ovarian Cancer Drugs Market Size Worth $4.5 Billion by 2022: Grand View Research, Inc.
May 10, 2018
Sierra Oncology Reports First Quarter Results